CD274 and small cell lung carcinoma: Overall, the situation for SCLC appears to be very similar to that seen in other tumor types, where PD-1/PD-L1 inhibitors typically result in PFS curve two-phase decay, with one subpopulation deriving marked benefit and the other subpopulation appearing to derive little or no benefit [12].